BioSpace

Pfizer flat in Q3 despite 32% growth for new and acquired products

Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.

By BioSpace

1 min read
Pfizer flat in Q3 despite 32% growth for new and acquired products
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights